Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

Canada NewsWire July 31, 2017

ProMIS Neurosciences Announces CDN$3 Million Best-Efforts Private Placement

Canada NewsWire July 20, 2017

ProMIS Neurosciences Presents at AAIC 2017 Data from Alzheimer's Disease Program

Canada NewsWire July 19, 2017

ProMIS Neurosciences Provides Second Quarter Update for 2017 and Outlook for Near-Term Value Creation

Canada NewsWire July 10, 2017

ProMIS™ Neurosciences' Sponsored Research Agreement with University of British Columbia Receives Matching Grant from Canadian Institutes of Health Research

Canada NewsWire July 6, 2017

ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017

Canada NewsWire July 5, 2017

ProMIS Neurosciences Inc., Help for Alzheimer's, CEO Clip Video

Newsfile June 9, 2017

ProMIS™ Neurosciences Appoints William C. Mobley to Scientific Advisory Board

Canada NewsWire June 6, 2017

ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia

Canada NewsWire May 31, 2017

Prion 2017: Deciphering Neurodegenerative Disorders - 23-26 May 2017 Edinburgh

Canada NewsWire May 25, 2017

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer's Disease

Canada NewsWire May 24, 2017

ProMIS Neurosciences Announces Q1 2017 Annual Results

Canada NewsWire May 9, 2017

ProMIS Neurosciences to announce results in a presentation at the 2017 American Association of Neurology annual meeting

Canada NewsWire April 27, 2017

ProMIS Neurosciences announces results presented at the 13th International Conference on Alzheimer's and Parkinson's diseases held in Vienna, Austria

Canada NewsWire April 12, 2017

ProMIS Neurosciences announces overview of first quarter 2017 progress and outlook for near term value creation

Canada NewsWire March 30, 2017

ProMIS Neurosciences announces presentation and expert panel participation at the Neuroscience Biopartnering and Investment Forum held on March 27, 2017 at the New York Academy of Sciences

Canada NewsWire March 28, 2017

ProMIS Neurosciences Announces Appointment of Daniel Geffken as Chief Financial Officer

Canada NewsWire March 22, 2017

ProMIS Neurosciences Announces Fiscal 2016 Annual Results

Canada NewsWire March 15, 2017

ProMIS Neurosciences announces appointment of Anthony Giovinazzo to its Board of Directors

Canada NewsWire March 2, 2017

ProMIS Neurosciences successfully completes CDN$2.7 million private placement

Canada NewsWire February 23, 2017